ZANTAC 150
LOE ApproachingNDAORALTABLET, EFFERVESCENT
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 150 is an oral effervescent tablet containing ranitidine, a histamine-2 receptor antagonist indicated for gastric acid reduction and peptic ulcer disease management. The drug works by inhibiting histamine-mediated gastric acid secretion, providing symptomatic relief for acid-related conditions. It represents a mature, well-established therapeutic option in the H2-blocker class.
LOE Approaching
Product is transitioning toward loss of exclusivity with moderate competitive pressure (30%), signaling a contracting team focused on brand defense and generic preparation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
Working on ZANTAC 150 offers limited growth opportunity; roles focus on defending market share, managing generic transition, and supporting legacy brand operations at GSK. Career advancement is constrained by the product's LOE-approaching lifecycle and lack of clinical momentum.
Brand Manager (defensive/portfolio)
Worked on ZANTAC 150 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.